Edition:
United States

Advanced Accelerator Applications SA (AAAP.OQ)

AAAP.OQ on NASDAQ Stock Exchange Global Select Market

81.65USD
10:20am EST
Change (% chg)

$0.06 (+0.07%)
Prev Close
$81.59
Open
$81.63
Day's High
$81.68
Day's Low
$81.58
Volume
15,577
Avg. Vol
157,821
52-wk High
$81.74
52-wk Low
$23.50

Latest Key Developments (Source: Significant Developments)

Advanced Accelerator Applications Announces Commencement Of Novartis Tender Offer
Thursday, 7 Dec 2017 07:00am EST 

Dec 7 (Reuters) - Advanced Accelerator Applications Sa ::ADVANCED ACCELERATOR APPLICATIONS ANNOUNCES COMMENCEMENT OF NOVARTIS TENDER OFFER.ADVANCED ACCELERATOR APPLICATIONS - UNIT OF NOVARTIS COMMENCED CASH TENDER OFFER TO PURCHASE ALL OF CO'S ORDINARY SHARES FOR $41.00/SHARE, $82.00/ADS.ADVANCED ACCELERATOR APPLICATIONS SA - OFFER WILL EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, ON JANUARY 19, 2018, UNLESS EXTENDED.  Full Article

Advanced Accelerator Applications Board Recommends $3.9 Bln All Cash Tender Offer By Novartis
Tuesday, 5 Dec 2017 04:00pm EST 

Dec 5 (Reuters) - Advanced Accelerator Applications Sa ::ADVANCED ACCELERATOR APPLICATIONS BOARD OF DIRECTORS RECOMMENDS $3.9 BILLION ALL CASH TENDER OFFER BY NOVARTIS.ADVANCED ACCELERATOR APPLICATIONS - CO'S BOARD RECOMMENDS $3.9 BILLION ALL CASH TENDER OFFER BY NOVARTIS.  Full Article

Advanced Accelerator Applications reports qtrly loss per share EUR​ ‍0.26
Friday, 17 Nov 2017 07:38am EST 

Nov 17 (Reuters) - Advanced Accelerator Applications SA :Advanced Accelerator Applications reports 39% sales growth for third quarter 2017.Q3 sales rose 39 percent to $43.9 million.Advanced Accelerator Applications SA qtrly loss per share EUR​ ‍0.26.  Full Article

Advanced Accelerator Applications reports 32 pct sales growth in Q2
Thursday, 31 Aug 2017 07:00am EDT 

Aug 31 (Reuters) - Advanced Accelerator Applications SA :Advanced Accelerator Applications reports 32% sales growth for second quarter 2017.Q2 sales rose 32 percent to $41.7 million.Advanced Accelerator Applications SA - qtrly loss per share €0.11.  Full Article

Advanced Accelerator Applications completes resubmission of NDA
Thursday, 27 Jul 2017 07:00am EDT 

July 27 (Reuters) - Advanced Accelerator Applications Sa ::Advanced accelerator applications completes resubmission of NDA for lutetium lu 177 dotatate (lutathera®) to FDA.Advanced Accelerator Applications - resubmitted NDA following receipt of a complete response letter (CRL) from FDA in December 2016.  Full Article

CEO of biotech firm AAA says to refile Lutathera with FDA this month
Friday, 21 Jul 2017 11:47am EDT 

July 21 (Reuters) - Advanced Accelerator Applications CEO Stefano Buono tells Reuters::Will refile Lutathera application with U.S. FDA this month.  Full Article

Advanced Accelerator Applications' Q1 sales $34.9 million
Wednesday, 31 May 2017 07:00am EDT 

May 31 (Reuters) - Advanced Accelerator Applications Sa :Advanced Accelerator Applications reports 21% sales growth for first quarter 2017.Q1 sales rose 21 percent to $34.9 million.‍on track to resubmit NDA for lutetium lu 177 dotatate (lutathera®) to FDA in mid-2017​.‍net loss for quarter was EUR 11.3 million, compared to a net loss of EUR 3.0 million for Q1 of 2016.​.Advanced Accelerator Applications Sa qtrly diluted loss per share EUR 0.13.  Full Article

Advanced Accelerator Applications signs strategic supply agreement with University of Missouri
Thursday, 30 Mar 2017 07:30am EDT 

Advanced Accelerator Applications SA : Advanced Accelerator Applications signs strategic supply agreement with University Of Missouri for lutetium 177 . Advanced Accelerator Applications - announced a 10-year exclusive supply agreement for lutetium 177 with university of missouri research reactor .Through agreement, MURR will supply co with GMP-quality lutetium 177 chloride.  Full Article

Advanced Accelerator Applications receives complete response letter from FDA for Lutathera
Wednesday, 21 Dec 2016 07:00am EST 

Advanced Accelerator Applications Sa : Advanced Accelerator Applications receives complete response letter from FDA for Lutathera, an investigational treatment for neuroendocrine tumors .Advanced Accelerator Applications - No additional clinical studies were requested in CRL and no comments at this time on other sections of NDA submission.  Full Article

Advanced Accelerator Applications reports 24.4% sales growth in Q2
Wednesday, 31 Aug 2016 07:00am EDT 

Advanced Accelerator Applications Sa : Advanced Accelerator Applications reports 24.4% sales growth in the second quarter of 2016 . Q2 sales rose 24.4 percent to eur 27.64 million .Qtrly loss per share eur 0.02.  Full Article